Reviews on Clinical Pharmacology and Drug TherapyReviews on Clinical Pharmacology and Drug TherapyОбзоры по клинической фармакологии и лекарственной терапии1683-41002542-1875Eco-Vector69133010.17816/RCF691330ReviewsНаучные обзорыUnknownFeatures of metabolic cell death: ferroptosis, cuproptosis, disulfideptosis, lysozinctosis, alkaliptosis in cancer. Pharmacological basis of drug therapyОсобенности метаболической гибели клеток: ферроптоза, купроптoза, дисульфидптоза, лизоцинктоза, алкалиптоза при раке. Фармакологический базис лекарственной терапииhttps://orcid.org/0000-0002-3908-143XVashchenkoVladimir IvanovichВащенкоВладимир Иванович
Russian Federation

Senior Researcher, Dept of Blood and Tissues

старший научный сотрудник Центра крови и тканей

vladimir-vaschenko@yandex.ruhttps://orcid.org/0000-0003-1464-1127ShabanovPetrШабановПетр Дмитриевич
Russian Federation

Professor, Dr. Med. Sci. (Pharmacology), Head of the Department

доктор медицинских наук, профессор, заведующий отделом

pdshabanov@mail.ruKirov Military Medical AcademyФГБВОУ ВО "Военно-медицинская академия им. С.М. Кирова" МО РФInstitute of Experimental Medicine, St. PetersburgИнститут экспериментальной медицины, Санкт-Петербург07022026112509202507022026Copyright ©; , Eco-VectorCopyright ©; , Эко-ВекторEco-VectorЭко-Векторhttps://eco-vector.com/for_authors.php#07https://journals.eco-vector.com/RCF/article/view/691330

Fastness of tumoral cells to destruction in comparison with a healthy tissue represents a distinctive sign of cancer cells (effect of Varburg). Recent studies have identified metabolic cell death as unique forms of regulated cell death resulting from an imbalance in the cellular metabolism. Cell death is critical for the development and homeostasis of almost all multicellular organisms. Moreover, its dysregulation leads to diverse disease states. Historically, apoptosis was thought to be the major regulated cell death pathway, whereas necrosis was considered to be an unregulated form of cell death. However, research in recent decades has uncovered several forms of regulated necrosis that are implicated in degenerative diseases, inflammatory conditions and cancer. The growing insight into these regulated, non-apoptotic cell death pathways has opened new avenues for therapeutic targeting. Here, we describe the regulatory pathways of necroptosis, pyroptosis, parthanatos, ferroptosis, cuproptosis, lysozincrosis and disulfidptosis. This review discusses the mechanisms of metabolic cell death and explores their potential in cancer therapy. review underscores the complexity of the metabolic cell death pathways and offers insights into innovative therapeutic avenues for cancer treatment.

In the article, we discuss small-molecule inhibitors of the pathways and prospects for future drug discovery. Together, the complex mechanisms governing these pathways offer strategies to develop therapeutics that control non-apoptotic cell death.

Устойчивость опухолевых клеток к гибели в сравнении со здоровой тканью представляет собой отличительный признак раковых клеток (эффект Варбурга). Недавние исследования идентифицировали метаболический некроз клеток как уникальные формы отрегулированного некроза клеток, следующего из дисбалланса в клеточном метаболизме. Некроз клеток важен для развития и гомеостаза почти всех многоклеточных организмов. Кроме того, дисрегуляция некроза приводит к разнообразным болезненным состояниям. Исторически, апоптоз, как полагали, был запрограммированным путем разрушения клеток главного предмета специализации, тогда как некроз, по определению, являлся нерегулируемой формой гибели клеток. Однако исследования, выполненные в последние десятилетия, раскрыли несколько важных форм регулируемой гибели клеток, которые являются частью механизма дегенеративных заболеваний, воспалительных заболеваний и рака. Растущее понимание этих регулируемых, неапоптозных путей гибели клеток открывают новые перспективы для терапевтических стратегий. Здесь, мы описываем регулирующими путями гибели клеток: некроптозом, феррроптозом, купроптозом, аутофагией, лизоцинктозом и дисульфидптoзом. В статье обсуждаются механизмы метаболической гибели клеток и исследует их потенциал в терапии рака. Подчеркивается сложность метаболических путей гибели клеток и предлагаются новаторские идеи проникновения в суть терапевтических перспектив для лечения рака.

В статье обсуждаются ингибиторы малых молекул регулирующих путей и перспектив будущего изобретения лекарства против рака. Вместе взятые сложные механизмы, управляющие этими проводящими путями, предлагают стратегии по разработке терапии, которые включают разные формы неапоптозной гибели клеток.

Ferroptosis, Cuproptosis, Disulfidptosis, Lisolzinсrosis, Alcaliptosis, Regulated cell deathрегулируемая клеточная гибель, ферроптоз, купроптоз, дисульфидптоз, лизоцинктоз, алкалиптозKirov Military Medical AcademyВоенно-медицинская академия им. С.М. Кирова МО РФ1. Hotchkiss RS, Strasser A, McDunn JE. et al. Cell death. N Engl J Med. 2009;361(16):1570–1583.doi: 10.1056/NEJMra0901217.2. Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21(11):678–695.doi: 10.1038/ s41580-020-0270-8.3. Galluzzi L, Vitale I, Aaronson SA. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.doi: 10.1038/s41418-017-0012-4.4. Tang D, Kang R, Berghe TV. et al. The molecular machinery of regulated cell death. Cell Res. 2019;29(5):347–364.doi: 10.1038/s41422-019-0164-5.5. Green DR, Victor B. The pantheon of the fallen: why are there so many forms of cell death? Trends Cell Biol. 2012;22(11):555–556.doi: 10.1016/j.tcb.2012.08.008.6. Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355–377.doi: 10.1016/j.cmet.2022.01.007.7. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417. doi: 10.1038/s41571-020-0341-y.8. Hadian K, Stockwel BR. The thetapeutic potencial of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov. 2023;22(9):471–485.doi: 10.1038/s41573-023-00749-8.9. Koren E, Fuchs Y. Modes of regulated cell death in cancer. Cancer Discov. 2021;11(2):245–265.doi: 10.1158/2159-8290.CD-20-0789.10. Leak L, Dixon SJ. Surveying the landscape of emerging and understudied cell death mechanisms. Biochim Biophys Acta Mol Cell Res. 2023;1870(3):119432.doi: 10.1016/j.bbamcr.2023.119432.11. Tsvetkov P, Coy S, Petrova B. et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254–1261.doi: 10.1126/science.abf0529.12. Dixon SJ, Lemberg KM, Lamprecht MR. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.doi: 10.1016/j.cell.2012.03.042.13. Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15(9):642-660.doi:10.1093/procel/pwae003.14. Jiang L, Jia J, Zhai Y, et al. Eddaoudi M, Zhu G. Chem Commun (Camb). Correction: Unusual design strategy for a stable and soluble high-molecular-weight copper (I) arylacetylide polymer. 2021;57(95):12856. doi:10.1039/d1cc90407h.15. Vaschenkо V.I., Sоrokoletova Е.F., Shаbаnоv P.D. Modern representations about signaling pathways and protective mechanisms of ferroptosis. A biological role of diffusion of death signals of ferroptotic cells. Reviews on Clinical Pharmacology and Drug Therapy. 2023;21(3):195–214.doi:10.17816/RCF567780.16. Liu Y, Gu W. p53 in ferroptosis regulation: the new weapon for the old guaedian. Cell Death Dif. 2022;29(5):1913-1924.doi: 10.1038/s41418-022-00943-y.17. Chen D, Chu B, Yang X. et al. iPLA2beta-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4.Nat Commun. 2021;12(1):3644.doi:10.1038/s41467-021-23902-6.18. Yang X, Wang Z, Zandkarimi F. et al. Regulation of VKORC1L1 is critical for p53-mediated tumor suppression through vitamin K metabolism. Cell Metab. 2023;35(8):1474–1490. e8.doi:10.1016/j.cmet.2023.06.014.19. Tarangelo A, Magtanong L, Bieging-Rolett KT. et al. p53 Suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep. 2018;22(3):569–575.doi: 10.1016/j.celrep.2017.12.077.20. Xie Y, Zhu S, Song X. et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 2017;20(7):1692–1704.doi: 10.1016/j.celrep.2017.07.055.21. Gao M, Yi J, Zhu J. et al. Role of mitochondria in ferroptosis. Mol Cell. 2019;73(2):354–363.e3.doi: 10.1016/j.molcel.2018.10.042.22. Koppula P, Lei G, Zhang Y. et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun. 2022;13(1):2206.doi: 10.1038/s41467-022-29905-1.23. Sun X, Ou Z, Chen R. et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173–184.doi: 10.1002/hep.28251.24. Zhang Y, Shi J, Liu X. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20(10):1181-1192.doi: 10.1038/s41556-018-0178-0.25. Su Z, Kon N, Yi J. et al. Specific regulation of BACH1 by the hotspot mutant p53(R175H) reveals a distinct gain of function mechanism. Nat Cancer. 2023;4(4):564–581.doi: 10.1038/s43018-023-00532-z.26. Yi J, Zhu J, Wu J. et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117(49):31189–31197.doi:10.1073/pnas.2017152117.27. Lei G, Zhuang L, Gan B. et al. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381-386.doi:10.1038/s41568-022-00459-0.28. Wu J, Minikes AM, Gao M. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature. 2019;572(7769):402–406.doi: 10.1038/s41586-019-1426-6.29. Yang WH, Ding CC, Sun T. et al. The Hippo Pathway Effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep. 2019;28(10):2501–2508.e4.doi: 10.1016/j.celrep.2019.07.107.30. Alborzinia H, Chen Z, Yildiz U. et al. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. EMBO Mol Med. 2023;15(8):e18014.doi:10.15252/emmm.202318014.31. Hangauer MJ, Viswanathan VS, Ryan MJ. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247–250.doi: 10.1038/nature24297.32. Viswanathan VS, Ryan MJ, Dhruv HD. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453–457.doi: 10.1038/nature23007.33. Feng H, Stockwell BR. Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol. 2018;16(5):e2006203.doi: 10.1371/journal.pbio.2006203.34. Cramer SL, Saha A, Liu J. et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat Med. 2017;23(1):120–127.doi: 10.1038/nm.4232.35. Zheng J, Sato M, Mishima E. et al. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 2021;12(7):698.doi: 10.1038/s41419-021-03998-w.36. Chen X, Comish PB, Tang D. et al. Characteristics and biomarkers of ferroptosis. Front Cell Dev Biol. 2021;9:637162.doi: 10.3389/fcell.2021.637162.37. Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 2022;22(7):381–396.doi: 10.1038/s41568-022-00459-0.38. Lang X, Green MD, Wang W. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673-1685.doi:10.1158/2159-8290.CD-19-0338.39. Lei G, Zhuang Y, Koppula P. et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146-162.doi: 10.1038/s41422-019-0263-3.40. Lei G, Zhuang Y, Hong T. et al. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. 2021;40(20):3533-3547.doi: 10.1038/s41388-021-01790-w.41. Wang W, Green M, Choi JE. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–274.doi: 10.1038/s41586-019-1170-y.42. Wengler MR, Talbot NJ. Mechanisms of regulated cell death during plant infection by the rice blast fungus Magnaporthe oryzae. Cell Death Dif. 2025.doi: 10.1038/s41418-024-01442-y43. Lei G, Zhuang L, Gan B. et al. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381-396.doi: 10.1038/s41568-022-00459-0.44. Eaton JK, Furst L, Ruberto RA. et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16(5):497–506.doi:10.1038/s41589-020-0501-5.45. Wang ME, Chen J, Lu Y. et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis. J Clin Invest. 2023a;133(10):e166647.doi: 10.1172/JCI166647.46. Tang D, Kroemer G, Kang R. Ferroptosis in immunostimulation and immunosuppression. Immunol Rev. 2023;321(1):199–210.doi: 10.1111/imr.13235.47. Xu H, Ye D, Ren M. et al. Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Trends Mol Med. 2021;27(9):856–867.doi: 10.1016/j.molmed.2021.06.014.48. Badgley MA, Kremer DM, Maurer HC. et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85–89.doi:10.1126/science.aaw9872.49. Liao P, Wang W, Wang W. et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365–378.e6.doi: 10.1016/j.ccell.2022.02.003.50. Kim R, Hashimoto A, Markosyan N. et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022;612(7939):338–346.doi:10.1038/s41586-022-05443-0.51. Cobine PA, Moore SA, Leary SC. Getting out what you put in: copper in mitochondria and its impacts on human disease. Biochim Biophys Acta Mol Cell Res. 2021;1868(1):118867.doi: 10.1016/j.bbamcr.2020.118867.52. Royer A, Sharman T. Copper toxicity. Treasure Island.(FL): StatPearls Publishing, 2025.53. Tsvetkov P, Cou S, Petrova B. et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254-1261. doi: 10.1126/science.abf.0529.54. Vashchenko VI, Chuklovin AB, Shabanov PD. Copper-dependent cell death (cuproptosis): perspectives for pharmacological correction in human diseases. Psychopharmacology and biological narcology. 2024;15(4):287–324. DOI: https://doi.org/10.17816/phbn641854.55. Ge EJ, Bush AL, Casini A. et al. Connecting copper and cancer: from transition metal signaling to metalloplasia. Nat Rev Cancer. 2022;22:102-113.doi: 10.1016/j.cbpa.2017.11.003.56. Nagai M, Vo NH, Shin Ogawa L. et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med 2012;52(10):2142–2150.doi: 10.1016/j.freeradbiomed.2012.03.017.57. Tsvetkov P, Detappe A, Cai K. et al. Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019;15(7):681–689.doi: 10.1038/s41589-019-0291-9.58. Zheng P, Zhou C, Lu L. et al. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res. 2022;41(1):271.doi:10.1186/s13046-022-02485-0.59. Hedley D, Shamas-Din A, Chow S. et al. A phase I study of elesclomol sodium in patients with acute myeloid leukemia. Leuk Lymphoma. 2016;57(10):2437–2440.doi: 10.3109/10428194.2016.1138293.60. O’Day S, Gonzalez R, Lawson D. et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009;27(32):5452–5458.doi:10.1200/JCO.2008.17.1579.61. O’Day SJ, Eggermont AM, Chiarion-Sileni V. et al. Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol 2013;31(9):1211–1218.doi:10.1200/JCO.2012.44.5585.62. Veverka KA, Johnson KL, Mays DC. et al. Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoyl-sulfoxide. Biochem Pharmacol 1997;53(4):511–518.doi:10.1016/s0006-2952(96)00767-8.63. Gan Y, Liu T, Feng W. et al. Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways. Oncol Res 2023;31(3):333–343. DOI:10.32604/or.2023.028694.64. Chen SY, Chang YL, Liu ST. et al. Differential cytotoxicity mechanisms of copper complexed with disulfiram in oral cancer cells. Int J Mol Sci. 2021;22(7):3711.doi: 10.3390/ijms22073711.65. Triscott J, Lee C, Hu K. et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012;3(10):1112–1123.doi:10.18632/oncotarget.604.66. Huang J, Campian JL, Gujar AD. et al. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol. 2016;128(2):259–266.doi:10.1007/s11060-016-2104-2.67. Shimada K, Reznik E, Stokes ME. et al. Copper-binding small molecule induces oxidative stress and cell-cycle arrest in glioblastoma-patient-derived cells. Cell Chem Biol. 2018;25(5):585–594.e7.doi:10.1016/j.chembiol.2018.02.010.68. Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28:2029–2044. doi: 10.1038/s41418-021-00814-y.69. Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell Mol Immunol. 2021;18:1106–1121.70. Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Sig Transduct Target Ther. 2022;7:286.71. Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40:153.72. Tang D, Kang R, Berghe T V, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29:347–364.73. Liu X, Nie L, Zhang Y. et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25(3):404–414.doi:10.1038/s41556-023-01091-2.74. Liu X, Olszewski K, Zhang Y. et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020;22(4):476–486.doi:10.1038/s41556-020-0496-x.75. Wang X, Lin J, Li Z. Wang M. In what area of biology has anew type of cell death been discovered? Biochim Biophys Acta - Rev Cancer. 2023;1878():188955. doi:76. Liu X, Zhuang L, Gan B. Disulfidptosis: disulfide stress – induced cell death. Trends Cell Biol. 2024;34(4):327-337. doi:10.1016/j.tcb.2023.07.009.77. Zheng P, Zhou C, Ding Y, Duan S. Disulfidptosis: a neu target for metabolic cancer therapy. J Exp Clin Cancer Res. 2023;42(1):1-4. doi:10.1186/s13046-023-02675-4.78. Xiao F, Yang B, Xu F. et al. Disulfidptosis: A new type of cell death. Apoptosis. 2024;29:1309-1329. doi:10.1007/s.10495-024-01989-8.79. Rahman NSA, Zahari S, Syafruddin SE. et al. Functions and mechanisms of protein disulfide isomerase family in cancer emergence. Cell Biosci. 2022;12(1):129. doi:10.1186/s13578-022-00868-6.80. Tyo KEJ, Liu Z, Petranovic D, Nielsen J. Imbalance of heterologous protein folding and disulfide bond formation rates yields runaway oxidative stress. BMC Biol. 2012;10:16. doi: 10.1186/1741-7007-10-16.81. Zhong Z, Zhang C, Ni S. et al. NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors. Redox Biol. 2023;63:102711. doi: 10.1016/j.redox.2023.102711.82. Liu X, Zhang Y, Zhuang L et al. NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes Dis 2021;8(6):731–745.doi:10.1016/j.gendis.2020.11.010.83. Li S, Lu Z, Sun R. et al. The role of SLC7A11 in Cancer: friend or foe? Cancers (Basel). 2022;14(13):3059.doi:10.3390/cancers14133059.84. Cao L, Way M. The stabilization of Arp2/3 complex generated actin filaments. Biochem Soc Trans. 2024;52(1):343–352. doi: 10.1042/BST20230638.85. Vettore L, Westbrook RL, Tennant DA. New aspects of amino acid metabolism in cancer. Br J Cancer. 2020;122(2):150–156. doi:10.1038/s41416-019-0620-5.86. Lelièvre P, Sancey L, Coll JL. et al. The multifaceted roles of copper in cancer: a trace metal element with dysregulated metabolism, but also a target or a bullet for therapy. Cancer. 2020;12(12):3594. doi:10.3390/cancers12123594.87. Mejillano MR, Kojima S, Applewhite DA. et al. Lamellipodial versus filopodial mode of the actin nanomachinery: pivotal role of the filament barbed end. Cell. 2004;118(3):363–373.88. Li T, Song Y, Wei L. et al. Disulfidptosis: a novel cell death modality induced by actin cytoskeleton collapse and a promising target for cancer therapeutics.Cell Commun Signal. 2024;22(1):491. doi: 10.1186/s12964-024-01871-9.89. Yan Y, Teng H, Hang Q. et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023;14:3673. doi: 10.1038/s41467-023-39401-9. 90. Zhong L, Chang W, Luo B. et al. Development and validation of a disulfidptosis and disulfide metabolism-related risk index for predicting prognosis in lung adenocarcinoma. Cancer Cell Int. 2024;24(1):2. doi:10.1186/s12935-023-03204-1.91. Jantas D, Chwastek J, Grygier B. et al. Neuroprotective effects of necrostatin-1 against oxidative stress-induced cell damage: an involvement of Cathepsin D inhibition. Neurotox Res. 2020;37(3):525–542. doi:10.1007/s12640-020-00164-6.92. Koppula P, Olszewski K, Zhang Y. et al. KEAP1 deficiency drives glucose dependency and sensitizes lung cancer cells and tumors to GLUT inhibition. Science. 2021;24(6):102649.doi: 10.1016/j.isci.2021.102649.93. Joly JH, Delfarah A, Phung PS. et al. A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose. J Biol Chem. 2020;295(5):1350–1365. doi:10.1074/jbc.RA119.011471.94. Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21–43.doi:10.1016/j.ccell.2018.03.022.95. Tang T, Yang ZY, Wang D et al. The role of lysosomes in cancer development and progression. Cell Biosci. 2020;10:131.96. Devinney MJ, Malaiyandi LM, Vergun O. et al. A comparison of Zn2+ and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transition. Cell Calcium. 2009;45(5):447-455. doi:10.1016/j.ceca.2009.03.002.97. Du W, Gu M, Hu M. et al. Lysosomal Zn(2+) release triggers rapid, mitochondria-mediated, non-apoptotic cell death in metastatic melanoma. Cell Rep. 2021;37(3):109848.doi: 10.1016/j.celrep.2021.109848.98. Hennigar SR, Kelley AM, McClung JP. Metallothionein and Zinc Transporter expression in circulating human blood cells as biomarkers of zinc status: a systematic review. Adv Nutr. 2016;7:735–746.doi:10.3945/an.116.012518.99. Chimienti F, Seve M, Richard S. et al. Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors. Biochem Pharmacol. 2001;62(1):51–62.doi: 10.1016/s0006-2952(01)00624-4.100. Desoize B. Metals and metal compounds in carcinogenesis. In Vivo. 2003;17(6): 529-539.101. Zhu Y, Costa M. Metals and molecular carcinogenesis.Carcinogenesis. 2020;41(9):1161-1172. doi: 10.1093/carcin/bgaa076.102. Palermo G, Spinello A, Saha A, Magistrato A. Frontiers of metal-coordinating drug design. Expert Opin Drug Discov. 2021;16(5):497-511. doi: 10.1080/17460441.2021.1851188.103. Ding WQ, Lind SE. Metal ionophores - an emerging class of anticancer drugs. IUBMB Life. 2009; 61(11): 1013-1018. doi:10.1002/iub.253.104. Steinbrueck A, Sedgwick AC, Brewster JT. et al. Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents. Chem Soc Rev. 2020; 49(12): 3726-3747. doi:10.1039/C9CS00373H.105. Costello LC, Franklin RB. Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity. Expert Rev Anticancer Ther. 2012;12(1): 121-128. doi:10.1586/era.11.190.106. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005; 65(8): 3389-3395. doi:10.1158/0008-5472.CAN-04-3577.107. University Health Network, Toronto. Phase 1 Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy. 2015 Accessed November 9,2021. https://clinicaltrials.gov/ct2/show/NCT00963495.108. Schimmer AD, Jitkova Y, Gronda M. et al. A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2012; 12(5): 330-336. doi:10.1016/j.clml.2012.05.005.109. Brar SS, Grigg C, Wilson KS. et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther. 2004; 3(9):1049-1060.110. Serra R, Zhao T, Huq S. et al. Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model. PLoS One. 2021;16(11): e0251957.doi: 10.1371/journal.pone.0251957.111. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4(5): 349-360. doi:10.1038/nrc1361.112. Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat. 1999; 2(4): 215-223. doi:10.1054/drup.1999.0095.113. Gelman JS, Sironi J, Berezniuk I. et al. Alterations of the intracellular Peptidome in response to the proteasome inhibitor Bortezomib. PloS One. 2013; 8(1):e53263. doi:10.1371/journal.pone.0053263.114. Cho YE, Lomeda RAR, Ryu SH. et al. Cellular Zn depletion by metal ion chelators (TPEN, DTPA and chelex resin) and its application to osteoblastic MC3T3-E1 cells. Nutr Res Pract. 2007; 1(1): 29-35. doi:10.4162/nrp.2007.1.1.29.115. Hyun HJ, Sohn JH, Ha DW. et al. Depletion of intracellular zinc and copper with tpen results in apoptosis of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(2):460-465.116. Yu Z, Yu Z, Chen Z. et al. Zinc chelator TPEN induces pancreatic cancer cell death through causing oxidative stress and inhibiting cell autophagy. J Cell Physiol. 2019; 234(11): 20648-20661. doi:10.1002/jcp.28670.117. Donadelli M, Dalla Pozza E, Costanzo C. et al. Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. J Cell Biochem. 2008;104(1): 202-212. doi:10.1002/jcb.21613.118. Kimura T, Kambe T. The Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective. Int J Моl Sciences. 2016;17(3):336. doi: 10.3390/ijms17030336.119. Lagadic-Gossmann D, Huc L, Lecureur V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ. 2004;11(9):953–961.doi: 10.1038/sj.cdd.4401466.120. Wang YZ, Wang JJ, Huang Y. et al. Tissue acidosis induces neuronal necroptosis via ASIC1a channel independent of its ionic conduction. Elife. 2015;4:e05682.doi: 10.7554/eLife.05682.121. Xu T, Su H, Ganapathy S. et al. Modulation of autophagic activity by extracellular pH. Autophagy. 2011;7(11):1316–1322.doi: 10.4161/auto.7.11.17785.122. Chen F, Kang R, Liu J, Tang D. Mechanism of alkaliptosis. Front Cell Develop Biol. 2023;11:1213995.doi: 10.3389/f.cell.2023.1213995.123. Liu J, Kuang F, Kang R. et al. Alcaliptosis: a new weapon for cancer therapy. Cancer GeneTher. 2020;27(5):267–269.doi: 10.1038/s41417-019-0134-6.124. Swietach P, Patiar S, Supuran CT. et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem. 2009;284(30):20299–20310.doi: 10.1074/jbc.M109.006478.125. McIntyre A, Hulikova A, Ledaki I. et al. Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth. Cancer Res. 2016;76(13):3744-3755. doi: 10.1158/0008-5472.CAN-15-1862.126. Zhu S, Liu J, Kang R. et al. Targeting NF-kappaB-dependent alcaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells. Biochem Biophys Res Commun. 2021;562:55-61.doi:10.1016/j.bbrc.2021.05.049.127. Hu M, Li P, Wang C. et al. Parkinson's disease-risk protein TMEM175 is a proton-activated proton channel in lysosomes. Cell. 2022;185(13):2292–2308.e20.doi: 10.1016/j.cell.2022.05.021.128. Kanai Y. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther. 2022;230:107964. doi: 10.1016/j.pharmthera.2021.107964.129. Dai Z, Liu WC, Chen XY, Wang X, Li JL, Zhang X. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors. Front Immunol. 2023;14:1178662. doi: 10.3389/fimmu.2023.1178662.130. Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biology. 2024;25(5):379–395. doi: 10.1038/s41580-023-00689-6.